# Ingrezza Sprinkle (valbenazine tosylate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/valbenazine

> The FDA approved Ingrezza Sprinkle (valbenazine tosylate), sponsored by NEUROCRINE BIOSCIENCES INC (NBIX), on April 30, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Ingrezza Sprinkle (valbenazine tosylate) |
| Codes | NBI-98854 |
| Sponsor | NEUROCRINE BIOSCIENCES INC (NBIX) https://sec-api.dev/companies/nbix/catalysts |
| Indications | [Chorea, Huntington](https://sec-api.dev/indications/chorea-huntington), Dyskinesia |
| Modality |  |
| FDA designations | priority review |

## Timeline

### April 11, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209241 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170411, review_priority PRIORITY; sponsor_name NEUROCRINE; product INGREZZA (VALBENAZINE TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209241%22

### April 23, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209241 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20210423, review_priority STANDARD; sponsor_name NEUROCRINE; product INGREZZA (VALBENAZINE TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209241%22

### August 18, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209241 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20230818, review_priority STANDARD; sponsor_name NEUROCRINE; product INGREZZA (VALBENAZINE TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209241%22

### April 30, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218390 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240430, review_priority STANDARD; sponsor_name NEUROCRINE; product INGREZZA SPRINKLE (VALBENAZINE TOSYLATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218390%22

### October 16, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Dyskinesia; Cerebral Palsy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05206513 (Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-16 (ACTUAL); Lead Sponsor Neurocrine Biosciences." https://clinicaltrials.gov/study/NCT05206513

### November 5, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 3. Indication: Chorea, Huntington.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04400331 (Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-05 (ACTUAL); Lead Sponsor Neurocrine Biosciences." https://clinicaltrials.gov/study/NCT04400331

### April 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chorea, Huntington.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06312189 (Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." https://clinicaltrials.gov/study/NCT06312189

### Apr to Jul 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chorea, Huntington.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06312189 (Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." https://clinicaltrials.gov/study/NCT06312189

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/valbenazine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ingrezza Sprinkle (valbenazine tosylate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/valbenazine

```bibtex
@misc{secapidev_pdufa_valbenazine_20261116,
  title        = {Ingrezza Sprinkle (valbenazine tosylate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/valbenazine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_valbenazine_20261116","title":"Ingrezza Sprinkle (valbenazine tosylate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/valbenazine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
